Suck Chei Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suck Chei Choi has a total of 364 co-authors. Here are the top co-authors by number of shared publications:
- Geom Seog Seo
Department of Internal Medicine and Digestive Disease Research Institute, Wonkwang University School of Medicine, Iksan, Korea
13 shared publications - Yong Sung Kim
Digestive Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Korea
11 shared publications - Ju Yup Lee
Department of Internal Medicine Keimyung University School of Medicine Daegu Korea
10 shared publications - Nayoung Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
10 shared publications - Gwang Ho Baik
Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea
9 shared publications - Gwang Ha Kim
Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
8 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (4) , 565-576
Psychological Predictors of Symptom Severity in Disorders of Gut–Brain Interaction: A Machine Learning Approach
Sung-Hoon Yoon, Dawoon Jung, Dae-Jin Kim, Chan-mo Yang, Young Hyeon Ahn, June-Woo Kim, Yong-Sung Kim, Suck-Chei Choi, and Sang-Yeol Lee. J Neurogastroenterol Motil 2026;32:565-76. https://doi.org/10.5056/jnm25246
- 30 October 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (4) , 565-576
Open AccessPsychological Predictors of Symptom Severity in Disorders of Gut–Brain Interaction: A Machine Learning Approach
Sung-Hoon Yoon, Dawoon Jung, Dae-Jin Kim, Chan-mo Yang, Young Hyeon Ahn, June-Woo Kim, Yong-Sung Kim, Suck-Chei Choi, and Sang-Yeol Lee. J Neurogastroenterol Motil 2026;32:565-76. https://doi.org/10.5056/jnm25246
- Open Access
- 30 July 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (3) , 307-309
Beyond Dysbiosis Restoration: Does the Success of Fecal Microbiota Transplantation for Irritable Bowel Syndrome Lie in Repairing the Intestinal Stem Cell Niche?
Yong Sung Kim and Suck Chei Choi. J Neurogastroenterol Motil 2026;32:307-9. https://doi.org/10.5056/jnm26132
- 30 July 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (3) , 307-309
Open AccessBeyond Dysbiosis Restoration: Does the Success of Fecal Microbiota Transplantation for Irritable Bowel Syndrome Lie in Repairing the Intestinal Stem Cell Niche?
Yong Sung Kim and Suck Chei Choi. J Neurogastroenterol Motil 2026;32:307-9. https://doi.org/10.5056/jnm26132
- Open Access
- 22 June 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 551-561
A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs
Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcers. Tegoprazan, a novel potassium-competitive acid blocker, provides rapid and potent inhibition of acid production. This study evaluated whether tegoprazan 25 mg is non-inferior to lansoprazole 15 mg in preventing NSAID-induced peptic ulcer. In this double-blind, randomized, active-controlled, multicenter phase III trial, patients requiring NSAIDs for up to 24 weeks were randomized (1:1) to the tegoprazan or the lansoprazole group. The primary endpoint was the incidence of peptic ulcer at week 24 in the per-protocol population. Secondary endpoints were NSAID-induced gastrointestinal symptom-free rates. Safety outcomes included adverse drug reactions (ADRs) and serious adverse events (SAEs). A total of 392 patients were randomized, and 269 patients were analyzed in the perprotocol set. Tegoprazan was non-inferior to lansoprazole for the prevention of gastroduodenal ulcers (p=0.0004). The heartburn-free rate at week 12 was higher in the tegoprazan group (p=0.0421), while other symptom-free rates did not differ significantly. In terms of safety, ADR and SAE rates were comparable and not significantly different. Tegoprazan was non-inferior to lansoprazole in preventing NSAID-induced peptic ulcers with excellent tolerance. Tegoprazan represents a clinically effective alternative gastroprotective therapy (ClinicalTrials.gov identifier NCT04840550).
- 22 June 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 551-561
Open AccessA Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs
Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcers. Tegoprazan, a novel potassium-competitive acid blocker, provides rapid and potent inhibition of acid production. This study evaluated whether tegoprazan 25 mg is non-inferior to lansoprazole 15 mg in preventing NSAID-induced peptic ulcer. In this double-blind, randomized, active-controlled, multicenter phase III trial, patients requiring NSAIDs for up to 24 weeks were randomized (1:1) to the tegoprazan or the lansoprazole group. The primary endpoint was the incidence of peptic ulcer at week 24 in the per-protocol population. Secondary endpoints were NSAID-induced gastrointestinal symptom-free rates. Safety outcomes included adverse drug reactions (ADRs) and serious adverse events (SAEs). A total of 392 patients were randomized, and 269 patients were analyzed in the perprotocol set. Tegoprazan was non-inferior to lansoprazole for the prevention of gastroduodenal ulcers (p=0.0004). The heartburn-free rate at week 12 was higher in the tegoprazan group (p=0.0421), while other symptom-free rates did not differ significantly. In terms of safety, ADR and SAE rates were comparable and not significantly different. Tegoprazan was non-inferior to lansoprazole in preventing NSAID-induced peptic ulcers with excellent tolerance. Tegoprazan represents a clinically effective alternative gastroprotective therapy (ClinicalTrials.gov identifier NCT04840550).
- Open Access
- 31 May 2026
- Published by The Korean Society of Sex-and Gender-Specific Biomedical Science in Sex- and Gender-Specific Biomedicine
- Vol. 1 (2) , 145-153
Sex Differences in Prevalence and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in Korea
Min Woo Lee, Nayoung Kim, Kwangwoo Nam, Sung Eun Kim, Gwang Ho Baik, Suck Chei Choi, Wan-Sik Lee, Hyun Jin Kim, Ju Yup Lee, Hyun Joo Song. Sex Gender Biomed 2026;1:145-53. https://doi.org/10.65400/SGBM.2026.1.2.145
- 31 May 2026
- Published by The Korean Society of Sex-and Gender-Specific Biomedical Science in Sex- and Gender-Specific Biomedicine
- Vol. 1 (2) , 145-153
Open AccessSex Differences in Prevalence and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in Korea
Min Woo Lee, Nayoung Kim, Kwangwoo Nam, Sung Eun Kim, Gwang Ho Baik, Suck Chei Choi, Wan-Sik Lee, Hyun Jin Kim, Ju Yup Lee, Hyun Joo Song. Sex Gender Biomed 2026;1:145-53. https://doi.org/10.65400/SGBM.2026.1.2.145
- Open Access
- 25 April 2026
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 23 (4) , 468-478
Subtype Comparison of Psychosocial Associations With Quality of Life in Functional Dyspepsia
Objective This study aimed to examine the associations of childhood trauma, psychosocial resources (social support and resilience), and emotional distress with quality of life (QoL) in patients with functional dyspepsia (FD), and to explore potential differences between the epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) subtypes.Methods This cross-sectional study included 152 FD patients and 79 healthy controls who completed the Korean versions of the following instruments: Beck Depression Inventory-II (K-BDI-II), Beck Anxiety Inventory (K-BAI), Childhood Trauma Questionnaire (KCTQ), Multidimensional Scale of Perceived Social Support (MSPSS), Connor-Davidson Resilience Scale (CD-RISC-K), and World Health Organization Quality of Life Assessment Instrument Brief Form (WHOQOL-BREF). Negative affect was computed as a principal component analysis-derived composite from K-BDI-II emotional/cognitive items and K-BAI; QoL was a composite of WHOQOLBREF domains. Group differences were assessed using analysis of variance, and hierarchical regression analysis identified predictors of QoL within the patient group. Finally, multivariate regression models compared subtype-specific psychosocial associations.Results Compared to controls, patients with FD reported higher emotional distress and childhood trauma, lower psychosocial resources and QoL. Negative affect was consistently associated with lower QoL in both subtypes (EPS: β=-0.360; PDS: β=-0.300). Although direct statistical comparison of pathways between subtypes showed no significant differences, the most prominent protective factor within each group appeared to differ: in the EPS group, higher social support was the most significant predictor of better QoL (β=0.381, p=0.001), whereas in the PDS group, resilience was the key protective factor (β=0.360, p=0.001).Conclusion Reducing emotional distress remains a central target for improving QoL in FD. Subtype-tailored emphases may be helpful— enhancing social support in EPS and bolstering resilience in PDS—while noting that between-subtype differences were limited and require confirmation in larger samples.
- 25 April 2026
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 23 (4) , 468-478
Open AccessSubtype Comparison of Psychosocial Associations With Quality of Life in Functional Dyspepsia
Objective This study aimed to examine the associations of childhood trauma, psychosocial resources (social support and resilience), and emotional distress with quality of life (QoL) in patients with functional dyspepsia (FD), and to explore potential differences between the epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) subtypes.Methods This cross-sectional study included 152 FD patients and 79 healthy controls who completed the Korean versions of the following instruments: Beck Depression Inventory-II (K-BDI-II), Beck Anxiety Inventory (K-BAI), Childhood Trauma Questionnaire (KCTQ), Multidimensional Scale of Perceived Social Support (MSPSS), Connor-Davidson Resilience Scale (CD-RISC-K), and World Health Organization Quality of Life Assessment Instrument Brief Form (WHOQOL-BREF). Negative affect was computed as a principal component analysis-derived composite from K-BDI-II emotional/cognitive items and K-BAI; QoL was a composite of WHOQOLBREF domains. Group differences were assessed using analysis of variance, and hierarchical regression analysis identified predictors of QoL within the patient group. Finally, multivariate regression models compared subtype-specific psychosocial associations.Results Compared to controls, patients with FD reported higher emotional distress and childhood trauma, lower psychosocial resources and QoL. Negative affect was consistently associated with lower QoL in both subtypes (EPS: β=-0.360; PDS: β=-0.300). Although direct statistical comparison of pathways between subtypes showed no significant differences, the most prominent protective factor within each group appeared to differ: in the EPS group, higher social support was the most significant predictor of better QoL (β=0.381, p=0.001), whereas in the PDS group, resilience was the key protective factor (β=0.360, p=0.001).Conclusion Reducing emotional distress remains a central target for improving QoL in FD. Subtype-tailored emphases may be helpful— enhancing social support in EPS and bolstering resilience in PDS—while noting that between-subtype differences were limited and require confirmation in larger samples.
- Open Access
- 30 January 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (1) , 86-98
Spatiotemporal Remodeling of Enteric Neural Pathways Underlies Colonic Dysmotility Following Spinal Cord Injury in Rats
Min Seob Kim, Sei Kim, Se Eun Ha, Hyun Seok Choi, Myeong Hwan Yu, Jisong You, Dahyun Seon, Do Hee Lee, Min Cheol Joo, Yong Sung Kim, Suck Chei Choi, Joong Goo Kwon, Kyung Sik Park, Hyun Jin Kim, Seungil Ro, and Moon Young Lee. J Neurogastroenterol Motil 2026;32:86-98. https://doi.org/10.5056/jnm25093
- 30 January 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (1) , 86-98
Open AccessSpatiotemporal Remodeling of Enteric Neural Pathways Underlies Colonic Dysmotility Following Spinal Cord Injury in Rats
Min Seob Kim, Sei Kim, Se Eun Ha, Hyun Seok Choi, Myeong Hwan Yu, Jisong You, Dahyun Seon, Do Hee Lee, Min Cheol Joo, Yong Sung Kim, Suck Chei Choi, Joong Goo Kwon, Kyung Sik Park, Hyun Jin Kim, Seungil Ro, and Moon Young Lee. J Neurogastroenterol Motil 2026;32:86-98. https://doi.org/10.5056/jnm25093
- Open Access
- 16 January 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 562-574
Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers
Kyung Sik Park, Hyun-Soo Kim, Jung-Hwan Oh, Woo Chul Chung, Suck Chei Choi, Si Hyung Lee, Tae Ho Kim, Dae Young Cheung, Gwang Ho Baik, Sun Moon Kim, Hang Lak Lee, Jeong Seop Moon, Cheol Woong Choi, Chongil Sohn, Kyoung Oh Kim, Byung-Wook Kim, Hye-Kyung Jung, Da Hyun Jung, Sung Soo Kim, Moo In Park, Ju Yup Lee, Gwang Ha Kim, Hee Seok Moon, Hoonjai Chun, Ki-Nam Shim, Woon Geon Shin, Chan Hyuk Park, Taeoh Kim, Sung Woo Jung, Hyunjin Kim, Sam Ryong Jee, Keemyung Lee, Yu Kyung Cho, Sung Chul Park, Jinwoong Cho, Chealwung Huh, Hyesoo Kwon, Jun Kim, John Kim, Jong-Jae Park. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250334
- 16 January 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 562-574
Open AccessRandomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers
Kyung Sik Park, Hyun-Soo Kim, Jung-Hwan Oh, Woo Chul Chung, Suck Chei Choi, Si Hyung Lee, Tae Ho Kim, Dae Young Cheung, Gwang Ho Baik, Sun Moon Kim, Hang Lak Lee, Jeong Seop Moon, Cheol Woong Choi, Chongil Sohn, Kyoung Oh Kim, Byung-Wook Kim, Hye-Kyung Jung, Da Hyun Jung, Sung Soo Kim, Moo In Park, Ju Yup Lee, Gwang Ha Kim, Hee Seok Moon, Hoonjai Chun, Ki-Nam Shim, Woon Geon Shin, Chan Hyuk Park, Taeoh Kim, Sung Woo Jung, Hyunjin Kim, Sam Ryong Jee, Keemyung Lee, Yu Kyung Cho, Sung Chul Park, Jinwoong Cho, Chealwung Huh, Hyesoo Kwon, Jun Kim, John Kim, Jong-Jae Park. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250334
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Sex-Specific Associations of Helicobacter pylori Seropositivity and Intestinal Metaplasia with Colorectal Adenoma: A Korean Multicenter Cross-Sectional Study
Kim HJ, et al. World J Mens Health. 2026 ;44:e69. https://doi.org/10.5534/wjmh.260174
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessSex-Specific Associations of Helicobacter pylori Seropositivity and Intestinal Metaplasia with Colorectal Adenoma: A Korean Multicenter Cross-Sectional Study
Kim HJ, et al. World J Mens Health. 2026 ;44:e69. https://doi.org/10.5534/wjmh.260174
- Open Access
- 30 July 2025
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 31 (3) , 401-402
From Trials to Practice: Exploring the Clinical Value of Potassium-competitive Acid Blockers
- 30 July 2025
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 31 (3) , 401-402
Open AccessFrom Trials to Practice: Exploring the Clinical Value of Potassium-competitive Acid Blockers
- Open Access
- 25 July 2025
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 85 (3) , 319-344
Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Chronic constipation is one of the most common digestive diseases encountered in clinical practice. Constipation manifests as a variety of symptoms, such as infrequent bowel movements, hard stools, feeling of incomplete evacuation, straining at defecation, a sense of anorectal blockage during defecation, and use of digital maneuvers to assist defecation. During the diagnosis of chronic constipation, the Bristol Stool Form Scale, colonoscopy, and a digital rectal examination are useful for objective symptom evaluation and differential diagnosis of secondary constipation. Physiological tests for functional constipation have complementary roles. They are recommended for patients who have failed to respond to treatment with available laxatives and those who are strongly suspected of having a defecatory disorder. As new evidence on diagnosing and managing functional constipation emerged, the need to revise the previous guideline was suggested. Therefore, these evidence-based guidelines have proposed recommendations developed using a systematic review and meta-analysis of the treatment options available for functional constipation. The benefits and cautions of new pharmacological agents (such as lubiprostone and linaclotide) and conventional laxatives have been described through a meta-analysis. The guidelines consist of 34 recommendations, including 3 concerning the definition and epidemiology of functional constipation, 9 regarding diagnoses, and 22 regarding management. Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding managing functional constipation.
- 25 July 2025
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 85 (3) , 319-344
Open AccessSeoul Consensus on Clinical Practice Guidelines for Functional Constipation
Chronic constipation is one of the most common digestive diseases encountered in clinical practice. Constipation manifests as a variety of symptoms, such as infrequent bowel movements, hard stools, feeling of incomplete evacuation, straining at defecation, a sense of anorectal blockage during defecation, and use of digital maneuvers to assist defecation. During the diagnosis of chronic constipation, the Bristol Stool Form Scale, colonoscopy, and a digital rectal examination are useful for objective symptom evaluation and differential diagnosis of secondary constipation. Physiological tests for functional constipation have complementary roles. They are recommended for patients who have failed to respond to treatment with available laxatives and those who are strongly suspected of having a defecatory disorder. As new evidence on diagnosing and managing functional constipation emerged, the need to revise the previous guideline was suggested. Therefore, these evidence-based guidelines have proposed recommendations developed using a systematic review and meta-analysis of the treatment options available for functional constipation. The benefits and cautions of new pharmacological agents (such as lubiprostone and linaclotide) and conventional laxatives have been described through a meta-analysis. The guidelines consist of 34 recommendations, including 3 concerning the definition and epidemiology of functional constipation, 9 regarding diagnoses, and 22 regarding management. Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding managing functional constipation.